Abstract: The disclosure relates to a method of producing an immune response in a warm-blooded animal comprising administering to said animal from about 0.1 to about 100 mg/Kg of body weight of a composition selected from the group consisting of a copolymer of olefin monomer and polycarboxylic anhydride having an average molecular weight of from about 300 to about 1500 in which said copolymer is derivatized to contain (a) half-amide, half-carboxyl acid groups and (b) imide groups in which said imide groups comprise from about 5% to about 40% by weight of said derivatized groups, and the pharmaceutically acceptable cationic salt derivatives of said derivatized copolymers.

Abstract: Pharmaceutical compositions for use in the relief of acute pulmonary edema, different types of shock including anaphylactic shock, shock induced by bacterial endotoxins, and hyperfibrinolysis induced by substances which activate plasminogen, consist of solutions of an ester of L-arginine with an aliphatic alcohol in water at a pH between 5.5 and 8.5. The compositions may be provided in unit dosage form containing 0.25-100 mg of active substance and are administered through the parenteral route. The esters may be provided in the form of a salt with a pharmaceutically acceptable organic or inorganic acid. The esters may be with methyl or ethyl alcohol. The compositions are more effective than aspirin and aprotinin.

Abstract: Increased intracranial pressure in warm-blooded animals is reduced by administering to the warm-blooded animals a therapeutically effective amount of a propanol derivative of the formula: ##STR1## wherein R is alkyl having one to 4 carbon atoms and Ring A is phenyl, halogenophenyl, methylphenyl or trifluoromethylphenyl, or a pharmaceutically acceptable acid addition salt thereof.

Abstract: Therapeutic xanthine oxidase inhibitor composition containing as an active ingredient 3-dimethylamino-7-methyl-1,2-(n-propylmalonyl)-1,2-dihydro-1,2,4-benzotria zine dihydrate of the formula ##STR1## Uratic diathesis in warm-blooded animals is therapeutically treated by administering the aforementioned xanthine oxidase inhibitor to such animals, e.g., human, either orally or by means of an injection, thereby inhibiting their xanthine oxidase activity.

Abstract: Aqueous solutions of pralidoxime salts are stabilized with hydroxylamine salts.

Abstract: Certain N-phenethylaminopropiophenones inhibit lipogenesis in mammals.

Abstract: New bendroflumethiazide formulations in solid form are provided which are characterized by excellent disintegration and dissolution capabilities even after long periods of storage. The new bendroflumethiazide formulations, for example, in the form of tablets, contain in addition to bendroflumethiazide, a combination of microcrystalline cellulose which serves as a diluent and aids in disintegration of the tablets, lactose which serves as a diluent, optionally starch (in the gelatinized form) which serves as a disintegrant, and one or more auxilliary disintegrants, such as sodium carboxymethyl starch, a tablet lubricant, such as magnesium stearate, and a colorant, if desired.A method for preparing the above formulations is also provided.

Abstract: This invention relates to a pharmaceutical use of 3-oxo-2,3-dihydro[1]benzothiophene-2-spirocyclopropane. The compound exhibits strong inhibition activity of thrombocyte aggregation in mammalian blood. The compound and its pharmaceutical composition are useful for the prophylaxis or treatment of cardiovascular disturbance such as thrombosis.

Abstract: A chewable anticonvulsant tablet dosage form consisting essentially of calcium valproate and a pharmaceutically acceptable carrier is disclosed. This novel dosage form is conveniently administered and is not irritating to the mucosa of the mouth and throat.

Abstract: An agricultural or horticultural miticidal composition for controlling mites which cause damage to plants, said miticidal composition comprising(1) a liquid carrier and/or a solid carrier, and(2) as an active ingredient, a trialkyltin compound of the formula ##STR1## wherein R.sup.1 represents a linear alkyl group having 6 to 11 carbon atoms, R.sup.2 represents a hydrogen atom or a methyl group, the total number of carbon atoms of R.sup.1 and R.sup.2 is from 7 to 11, m is an integer of 1 or 2, and X represents a chlorine atom, a bromine atom, a fluorine atom, a hydroxyl group, an acyloxy group, a dithiocarbamate group or a group of the formula --SR.sup.3, in which R.sup.3 represents an alkyl group having 1 to 12 carbon atoms or an aryl group, when m is 1, and a member selected from the class consisting of an oxygen atom, a sulfur atom and a sulfuric acid group when m is 2; and a method for controlling mites using the same.

Abstract: Certain heterocyclyl 2-(2-(4-hydroxyphenyl)-2-hydroxy-1-methyl)ethylamino)ethyl ketones inhibit lipogenesis in mammals.

Abstract: The invention relates to 1-isopropyl- and 1-isobutyl-3,7-dimethyl xanthines as medicaments. They have a sedative effect comparable with that of a standard neuroleptic.

Abstract: Derivates of L- and DL-hydroxyphenylglycines of the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein R is hydrogen or methyl, R.sup.1 is hydrogen, amino or alkoxy having from one to six carbon atoms and R.sup.2 is the residue of certain .alpha.-amino acids are useful in treating diseases and conditions which are characterized by reduced blood flow, oxygen availability or carbohydrate metabolism in the cardiovascular system. Derivatives of D-hydroxyphenylglycine of formula (II) are substantially inactive in treating such diseases and conditions.

Abstract: A tissue adhesive on the basis of human or animal proteins has a content of factor XIII and fibrinogen, the ratio of factor XIII to fibrinogen, expressed in units of factor XIII per gram of fibrinogen, amounting to at least 80. Furthermore, it contains a plasminogen-activator-inhibitor or plasmin-inhibitor in an amount of 20 to 2,000 KIU per ml.

Abstract: A process for stabilizing the coagulation factors II, VIII, XIII, antithrombin III and plasminogen against heat is described. The preparations obtained according to this process are practically free from coagulable fibrinogen.

Abstract: Certain ureides of substituted naphtholmonosulfonic acids and salts useful as inhibitors of connective tissue destruction.

Abstract: Method of suppressing cardiac arrhythmias compounds of the formula: ##STR1## wherein: Y is 2,6-dimethylphenyl, 2,5-dimethylphenyl, 5-bromo-2-methylphenyl, or 5-chloro-2-methylphenyl; andX is propenyl, propynyl, or cyclopropyl; or a non-toxic, pharmaceutically acceptable acid addition salt thereof.

Abstract: A stabilized aqueous solution of chlorine oxides containing boron, the solution formed by adding to 1000 parts of water, 4-15 parts by weight of sodium or potassium perborate, and 8-15 parts by weight of sodium peroxide or an equivalent amount of potassium peroxide, hydrogen peroxide, potassium percarbonate or sodium percarbonate, the solution having therapeutic value.

Abstract: A method for combating amebiasis in humans comprising orally administering to said humans an effective amount of a perborate-stabilized aqueous solution of chlorine oxides, said solution containing about 4-12% by weight of sodium or potassium perborate and a peroxide or percarbonate.

Abstract: Germanium-containing organic polymers are obtained by polymerizing 3-trichlorogermylpropionic acid obtained by reacting halogermanium-phosphoric acid complexes with acrylic acid. The polymers are markedly effective in treating opthalmological disorders.